Table 3.
Canonical pathways associated with dapivirine or placebo vaginal ring use.
| Arm | Comparison | Pathway | Proteins | P value |
| Dapivirine | Baseline versus visit 1 | ILK signaling | ACTN1, CDH1, MMP9 | 5.89E-04 |
| Dapivirine | Baseline versus visit 1 | Leukocyte extravasation signaling | ACTN1, MMP8, MMP9 | 6.61E-04 |
| Placebo | Baseline versus visit 1 | Remodeling of epithelial adherens junctions | ACTR2, ACTR3, ARPC2 | 4.17E-06 |
| Placebo | Baseline versus visit 1 | FcÎ3 receptor-mediated phagocytosis in macrophages and monocytes | ACTR2, ACTR3, ARPC2 | 1.10E-05 |
| Placebo | Baseline versus visit 1 | fMLP signalling in neutrophils | ACTR2, ACTR3, ARPC2 | 2.09E-05 |
| Placebo | Baseline versus visit 1 | CD28 signaling in T Helper cells | ACTR2, ACTR3, ARPC2 | 2.29E-05 |
| Placebo | Baseline versus visit 1 | Integrin signalling | ACTR2, ACTR3, ARPC2 | 1.26E-04 |